Pharmaceuticals, Biotechnology and Life Sciences
BRISBANE, Calif.–(BUSINESS WIRE)–Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. John Markels, an…
— Oligomerix’s lead compound targets tau self-association, the initial step before aggregate formation — — Drug reduced tau aggregates in…
New independent analysis by economic policy experts finds Teva saved the US healthcare system $41.9 billion in 2018 $5.9 billion…
Revenue of $2,895 million for the fourth quarter and $11,088 million for the full year Adjusted EBITDA of $642 million…
Viralym-M pivotal and proof-of-concept studies to be initiated in 2020 for treatment and prevention of severe and life-threatening viral diseases…
Study to Evaluate the Pressure-Enabled Drug Delivery™ Approach Combined with Standard of Care Chemotherapy to Enable Deep Tumor Penetration and…
– Completed Last Patient Last Visit for STRIDE 3 Dry Eye Disease Trial; Topline Results on Track for First Quarter…
TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter…
NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and…
In Pivotal Phase 3 KEYNOTE-355 Study, KEYTRUDA Plus Chemotherapy Significantly Improved PFS Compared to Chemotherapy Alone in Patients with mTNBC…